University Medical Center of Southern Nevada
Board of Hospital Trustees
AGENDA ITEM
|
Petitioner: |
Mason Van Houweling, Chief Executive Officer |
Recommendation:
title
Approve and authorize the Chief Executive Officer to sign the amendment to the Client Agreement, with Life Technologies Corporation for COVID-19 Related Products; or take other action as appropriate. (For possible action)
body
FISCAL IMPACT:
|
Fund #: |
5420.000 |
Fund Name: |
UMC Operating Fund |
|
Fund Center: |
3000991200 |
Funded PGM/Grant: |
N/A |
|
Amount: |
$17,303,906.97 |
|
Description: |
Supply Agreement for COVID-19 Related Products |
|
Additional Comments: |
Total Cumulative NTE funding of $44,777,562.97 |
BACKGROUND:
Since July 2020, UMC has had a Supply Agreement with Life Technologies Corporation (LTC) to purchase COVID-19 related products. Amendment 1, effective February, 2021, reduced the total NTE funding for the Agreement by 50% due to a decrease in demand.
This Amendment No. 2 seeks to: (i) add $17,303,906.97 in additional funds for the purchase of COVID-19 and flu-related laboratory products, including newly developed COVID-related or infectious disease products; and (ii) extend the term of Agreement through June 30, 2024, bringing the total NTE funding to $44,777,562.97.
UMC’s Director of Pathology has reviewed and recommends approval of this Amendment. This Amendment has been approved as to form by UMC’s Office of General Counsel.
The Department of Business License has determined that LTC is not required to obtain a Clark County business license, but must have a vendor registration. LTC has obtained its vendor registration.
This Amendment was reviewed by the Governing Board at their June 29, 2022 meeting and recommended for approval by the Board of Hospital Trustees.